Etanercept for severe psoriasis and psoriatic arthritis: Observations on combination therapy

British Journal of Dermatology

Volumn 146, Issue 1, 2002, Pages 118-121

  Iyer, S ^a   Yamauchi, P ^a   Lowe, Nicholas J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Combination therapy; Etanercept; Psoriasis; Tumour necrosis factor

Indexed keywords

CALCIPOTRIOL; CYCLOSPORIN; ETANERCEPT; ETRETIN; HYDROXYUREA; METHOTREXATE; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; FEMALE; HUMAN; IMMUNOMODULATION; MALE; PATHOGENESIS; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; TOXICITY;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME;

EID: 0036174873     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0007-0963.2001.04529.x     Document Type: Article

References (10)

1. Inhibitors of tumor necrosis factor: New treatment options for rheumatoid arthritis
2. Etancercept: A novel drug for the treatment of patients with severe, active rheumatoid arthritis
3. The role of tumor necrosis factor antagonism in clinical practice
4. Inhibitors of tumor necrosis factor for rheumatoid arthritis
5. Cytokines in psoriasis
6. Correlated increases of tumour necrosis factor-alpha, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients - Relationships with disease severity
7. Serum TNF-alpha levels correlate with disease activity and are reduced by effective therapy in plaque type psoriasis
8. Elevated tumour necrosis factor-alpha biological activity in psoriatic skin lesions
9. Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomized trial
10. Treatment with anti-tumor necrosis factor alpha monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions